


### Q1 Is your centre :

Answered: 62 Skipped: 0



Answer Choices	Responses
A private hospital (non-academic)	11.29% 7
A university hospital (academic)	79.03% 49
Other (please specify)	9.68% 6
<b>Total</b>	<b>62</b>

#	Other (please specify)	Date
1	Military Medical Instytut	7/18/2016 1:53 PM
2	County Public Hospital	7/14/2016 1:11 PM
3	District Hospital in Starachowice	7/13/2016 1:49 PM
4	Regional Hospital	7/13/2016 9:00 AM
5	Municipal hospital	7/12/2016 5:14 PM
6	Military Institute of Medicine - a hospital, with research part	6/30/2016 9:13 AM

EP Wire Survey on Stroke Prevention in Valvular AF : The European Heart Rhythm Association Survey

**Q2 In which country and city is your centre based ?**

Answered: 62 Skipped: 0


#	Responses	Date
1	SPAIN (Huelva)	7/31/2016 9:45 PM
2	SPAIN (Huelva)	7/31/2016 9:40 PM
3	TUNISIA - TUNIS	7/30/2016 11:24 AM
4	Belgium, Brussels	7/28/2016 9:07 PM
5	Norway	7/28/2016 2:32 PM
6	Latvia	7/26/2016 7:46 PM
7	Birmingham, United Kingdom	7/25/2016 9:41 PM
8	Poland	7/24/2016 4:13 PM
9	Poland	7/24/2016 4:09 PM
10	Austria and Linz	7/23/2016 5:16 PM
11	Spain	7/22/2016 11:06 AM
12	Romania, Tirgu Mures	7/21/2016 8:44 PM
13	Poland	7/21/2016 10:40 AM
14	SPAIN. MADRID	7/20/2016 9:23 PM
15	Spain	7/20/2016 2:12 PM
16	Trondheim, Norway	7/20/2016 9:49 AM
17	Germany	7/20/2016 8:20 AM
18	Poland, Warsaw	7/19/2016 9:38 PM
19	France	7/19/2016 7:18 PM
20	No	7/18/2016 1:53 PM
21	Poland, Bialystok	7/18/2016 12:01 AM
22	Germany	7/16/2016 5:28 AM
23	Poland Polanica Zdrój	7/15/2016 10:16 PM
24	Poland Rzeszow	7/14/2016 11:37 PM
25	Poland Warsaw	7/14/2016 7:46 PM
26	MADRID, SPAIN	7/14/2016 3:09 PM
27	Poland, Bielsko-Biała	7/14/2016 1:11 PM
28	Poland	7/14/2016 10:42 AM
29	Denmark	7/13/2016 2:59 PM
30	Poland Lodz	7/13/2016 1:51 PM
31	Poland, Starachowice	7/13/2016 1:49 PM
32	Poland, City Wroclaw	7/13/2016 9:43 AM
33	Poland, Starachowice	7/13/2016 9:00 AM
34	Poland, Lublin	7/12/2016 10:48 PM

## EP Wire Survey on Stroke Prevention in Valvular AF : The European Heart Rhythm Association Survey

35	Warsaw, Poland,	7/12/2016 6:37 PM
36	Poland Stalowa Wola	7/12/2016 5:14 PM
37	Poland, Warsaw	7/12/2016 4:14 PM
38	nn	7/12/2016 1:55 PM
39	Poland	7/12/2016 1:47 PM
40	Warsaw, Poland	7/12/2016 1:35 PM
41	Poland	7/12/2016 1:22 PM
42	Poland Katowice	7/12/2016 1:04 PM
43	Kraków	7/12/2016 1:03 PM
44	Poland, Warsaw	7/12/2016 12:08 PM
45	Italy, Florence	7/12/2016 11:43 AM
46	Belgrade, Serbia	7/7/2016 8:16 PM
47	Serbia, Belgrade	7/7/2016 2:05 AM
48	Poland	7/5/2016 10:43 PM
49	MADRID, SPAIN	7/2/2016 12:09 AM
50	Norway	7/1/2016 11:18 AM
51	Hasselt, Belgium	7/1/2016 10:31 AM
52	Georgia	6/30/2016 1:04 PM
53	Estonia	6/30/2016 12:12 PM
54	Linz, Austria	6/30/2016 10:50 AM
55	Bydgoszcz, Poland	6/30/2016 10:42 AM
56	France	6/30/2016 10:38 AM
57	Warsaw, Poland	6/30/2016 9:13 AM
58	Poland, Zabrze	6/30/2016 1:10 AM
59	Spain	6/29/2016 11:47 PM
60	Scotland, Aberdeen	6/29/2016 6:42 PM
61	France, Toulouse	6/29/2016 6:13 PM
62	Switzerland	6/29/2016 6:03 PM

**Q4 Which of the following would qualify your patient with atrial fibrillation (AF) for the diagnosis of 'valvular' AF? (Please select all that apply)**


Answered: 54 Skipped: 8



Answer Choices	Responses
a) The presence of a prosthetic mechanical heart valve	92.59% 50
b) The presence of a bioprosthetic heart valve	59.26% 32
c) Prior surgical valve repair (e.g., commissurotomy, valvuloplasty, annuloplasty, etc.)	53.70% 29
d) Prior transcatheter valve replacement/implantation	46.30% 25
e) Hypertrophic cardiomyopathy with a left ventricular outflow obstruction	14.81% 8
f) Significant rheumatic mitral valve stenosis	96.30% 52
g) Any significant native heart valve disease requiring surgery	42.59% 23
h) Any heart valvular abnormality	7.41% 4
i) I do not know	0.00% 0
<b>Total Respondents: 54</b>	

**Q5 Do you consider the rheumatic aetiology of valvular heart disease as a mandatory criterion for the diagnosis of 'valvular' AF in your AF patient?**


Answered: 54 Skipped: 8



Answer Choices	Responses
a) Yes, only AF patients with valvular disease with a rheumatic aetiology should be diagnosed with 'valvular' AF	20.37% 11
b) No, AF patients with sclerotic or other valvular disease should also be diagnosed with 'valvular' AF	75.93% 41
c) I do not know	3.70% 2
<b>Total</b>	<b>54</b>

**Q6 Do you consider only the involvement of mitral valve as relevant for the diagnosis of 'valvular' AF in your AF patient (whilst patients with other heart valve disease should be diagnosed with non-valvular AF)?**


Answered: 54 Skipped: 8



Answer Choices	Responses	
a) Yes	51.85%	28
b) No, the diagnosis of 'valvular' AF includes abnormalities of any of the heart valves	46.30%	25
c) I do not know	1.85%	1
<b>Total</b>		<b>54</b>

### Q7 Do you consider hemodynamic relevance of the valvular abnormality as a criterion for the diagnosis of 'valvular' AF?


Answered: 54 Skipped: 8



Answer Choices	Responses
a) Yes, 'valvular' AF should be diagnosed only in the presence of hemodynamically significant heart valve disease	70.37% 38
b) No, the presence of any heart valve abnormality qualifies the patient for the diagnosis of 'valvular AF'	27.78% 15
c) I do not know	1.85% 1
<b>Total</b>	<b>54</b>

**Q8 Do you consider a specific valvular abnormality (i.e., stenosis or insufficiency) as a criterion for the diagnosis of 'valvular' AF?**

Answered: 52 Skipped: 10




Answer Choices	Responses	
a) Yes, 'valvular' AF should be diagnosed only in the presence of a heart valve stenosis	44.23%	23
b) No	51.92%	27
c) I do not know	3.85%	2
<b>Total</b>		<b>52</b>



**Q9 Which of the following descriptive definitions would be a comprehensive definition of 'valvular AF', implying that all other AF patients not fitting the definition should be regarded (and treated) as having non-valvular AF?**


Answered: 52 Skipped: 10



Answer Choices	Responses
a) AF patients with a prosthetic mechanical heart valve or significant rheumatic mitral stenosis	26.92% 14
b) AF patients with a prosthetic mechanical heart valve, bioprosthetic heart valve, or significant rheumatic mitral stenosis	19.23% 10
c) AF patients with a prosthetic mechanical or bioprosthetic heart valve, or significant rheumatic mitral stenosis, or any other significant heart valve disease requiring surgical repair	42.31% 22
d) AF patients with any heart valve abnormality	5.77% 3
e) None of the above	5.77% 3
f) I do not know	0.00% 0
<b>Total</b>	<b>52</b>

### Q10 Which of the following drugs would you prescribe to your newly-diagnosed AF patient who has a mechanical prosthetic heart valve? (Please select all that apply)


Answered: 52 Skipped: 10



Answer Choices	Responses
a) a vitamin K antagonist (VKA), for example warfarin	96.15% 50
b) a non-vitamin K antagonist oral anticoagulant (NOAC)	0.00% 0
c) a VKA plus aspirin	1.92% 1
d) a VKA plus aspirin, in patients with mitral mechanical prosthetic valve	3.85% 2
e) a VKA plus aspirin, only if the patient has a history of prior stroke/TIA	13.46% 7
f) I do not know	0.00% 0
<b>Total Respondents: 52</b>	

**Q11 Which of the following drugs would you prescribe to your newly-diagnosed AF patient at risk of stroke who has a bioprosthetic heart valve?**


Answered: 52 Skipped: 10



Answer Choices	Responses
a) a vitamin K antagonist (VKA), for example warfarin	65.38% 34
b) a non-vitamin K antagonist oral anticoagulant (NOAC)	32.69% 17
c) a VKA plus aspirin	1.92% 1
d) aspirin or a P2Y12 inhibitor (i.e., clopidogrel, ticagrelor)	0.00% 0
e) I do not know	0.00% 0
<b>Total</b>	<b>52</b>

**Q12 Which of the following drugs would you prescribe to your AF patient at risk of stroke with a (non-recent) history of transcatheter valve replacement/implantation?**


Answered: 51 Skipped: 11



Answer Choices	Responses
a) a vitamin K antagonist (VKA), for example warfarin	47.06% 24
b) a non-vitamin K antagonist oral anticoagulant (NOAC)	41.18% 21
c) a VKA plus aspirin	11.76% 6
d) aspirin or a P2Y12 inhibitor (i.e., clopidogrel, ticagrelor)	0.00% 0
e) I do not know	0.00% 0
<b>Total</b>	<b>51</b>

### Q13 Would you consider using a NOAC in your AF patient with significant mitral stenosis?


Answered: 51 Skipped: 11



Answer Choices	Responses	
a) Yes	17.65%	9
b) No	82.35%	42
c) I do not know	0.00%	0
<b>Total</b>		<b>51</b>

### Q14 Would you consider using a NOAC in your AF patient with prior surgical valve repair?


Answered: 51 Skipped: 11



Answer Choices	Responses	
a) Yes	54.90%	28
b) No	43.14%	22
c) I do not know	1.96%	1
<b>Total</b>		<b>51</b>

**Q15 In which of the following conditions would you consider using a NOAC in your AF patient at risk of stroke? (please, select all that apply)**

Answered: 51 Skipped: 11




Answer Choices	Responses
a) AF and mitral regurgitation	60.78% 31
b) AF and aortic stenosis	58.82% 30
c) AF and aortic regurgitation	66.67% 34
d) AF and tricuspid regurgitation	74.51% 38
e) AF and pulmonary artery stenosis	62.75% 32
f) AF and pulmonary artery regurgitation	68.63% 35
g) No, I would not use oral anticoagulant therapy in AF patients without a conventional stroke risk factor (e.g., hypertension, age>65 years, prior stroke, etc.)	29.41% 15
h) I do not know	7.84% 4

Total Respondents: 51



**Q16 Would you consider using any oral anticoagulant therapy in your AF patient with a mild-to-moderate native (i.e., non-prosthetic) heart valve disease and no additional risk factors for stroke? (please select all that apply)**

Answered: 51 Skipped: 11




Answer Choices	Responses
a) Yes, in patients with mitral stenosis	56.86% 29
b) Yes, in patients with mitral regurgitation	29.41% 15
c) Yes, in patients with aortic stenosis	21.57% 11
d) Yes, in patients with aortic regurgitation	23.53% 12
e) Yes, in patients with a tricuspid valve abnormality	19.61% 10
f) Yes, in patients with a pulmonary valve abnormality	21.57% 11

## EP Wire Survey on Stroke Prevention in Valvular AF : The European Heart Rhythm Association Survey

g) No, I would not use oral anticoagulant therapy in AF patients without a conventional stroke risk factor (e.g., hypertension, age>65 years, prior stroke, etc.)	<b>33.33%</b>	17
h) I do not know	<b>1.96%</b>	1
<b>Total Respondents: 51</b>		

### Q17 Would you prefer using NOACs over VKAs in any of the following conditions? (please select all that apply)


Answered: 51 Skipped: 11



Answer Choices	Responses
a) Yes, in moderate-to-significant mitral stenosis	9.80% 5
b) Yes, in moderate-to-significant mitral regurgitation	49.02% 25
c) Yes, in moderate-to-significant aortic stenosis	45.10% 23
d) Yes, in moderate-to significant aortic regurgitation	50.98% 26
e) Yes, in a moderate-to-significant tricuspid valve disease	50.98% 26
f) Yes, in a moderate-to-significant pulmonary valve disease	49.02% 25
g) None of the above	25.49% 13
h) I do not know	11.76% 6
<b>Total Respondents: 51</b>	

**Q18 When you decide to prescribe a NOAC to your patient with 'valvular' AF, do you prefer a particular agent because of the presence of valvular heart disease?**


Answered: 51 Skipped: 11



Answer Choices	Responses
a) Yes, dabigatran	9.80% 5
b) Yes, rivaroxaban	3.92% 2
c) Yes, apixaban	3.92% 2
d) Yes, edoxaban	0.00% 0
e) No, I choose the NOAC according to individual patient overall risk profile	74.51% 38
f) I do not know	7.84% 4
<b>Total</b>	<b>51</b>

**Q19 Do you think that the available evidence on the use of NOACs in patients with 'valvular' AF is sufficient for clinical decision-making?**

Answered: 51 Skipped: 11



Answer Choices	Responses	
a) Yes	23.53%	12
b) No	74.51%	38
c) I do not know	1.96%	1
<b>Total</b>		<b>51</b>